奥曲肽长效释放制剂用于肾功能极低的常染色体显性多囊肾病患者：单中心真实世界经验 - Suppr

Octreotide-LAR in ADPKD patients with very low kidney function: a single-center real-life experience.

作者信息

Riccio Eleonora, Amicone Maria, Capuano Ivana, Pacella Daniela, Pisani Antonio

机构信息

Chair of Nephrology, Department of Public Health, Federico II University, Naples, Italy.

Department of Public Health, Federico II University, Naples, Italy.

出版信息

J Nephrol. 2024 Dec;37(9):2683-2685. doi: 10.1007/s40620-024-02145-w. Epub 2024 Nov 6.

DOI:10.1007/s40620-024-02145-w

PMID:39503964

Abstract

摘要

相似文献

Octreotide-LAR in ADPKD patients with very low kidney function: a single-center real-life experience.

J Nephrol. 2024 Dec;37(9):2683-2685. doi: 10.1007/s40620-024-02145-w. Epub 2024 Nov 6.

Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial.

Int J Cardiol. 2019 Jan 15;275:145-151. doi: 10.1016/j.ijcard.2018.10.063. Epub 2018 Oct 22.

Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.

PLoS Med. 2019 Apr 5;16(4):e1002777. doi: 10.1371/journal.pmed.1002777. eCollection 2019 Apr.

Effects of Octreotide-Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial.

Clin J Am Soc Nephrol. 2023 Feb 1;18(2):223-233. doi: 10.2215/CJN.0000000000000049.

Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.

Lancet. 2013 Nov 2;382(9903):1485-95. doi: 10.1016/S0140-6736(13)61407-5. Epub 2013 Aug 21.

Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.

Clin Gastroenterol Hepatol. 2016 Jul;14(7):1022-1030.e4. doi: 10.1016/j.cgh.2015.12.049. Epub 2016 Feb 1.

Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan.

Clin Exp Nephrol. 2015 Aug;19(4):746-52. doi: 10.1007/s10157-014-1047-1. Epub 2014 Oct 29.

Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature.

Clin Nephrol. 2022 Mar;97(3):131-140. doi: 10.5414/CN110510.

[ADPKD treatment: Tolvaptan and Octreotide].

G Ital Nefrol. 2019 Dec 9;36(6):2019-vol6.

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

J Am Soc Nephrol. 2010 Jun;21(6):1052-61. doi: 10.1681/ASN.2009121291. Epub 2010 Apr 29.

本文引用的文献

Glomerular hyperfiltration.

Nat Rev Nephrol. 2022 Jul;18(7):435-451. doi: 10.1038/s41581-022-00559-y. Epub 2022 Apr 1.

The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials.

Sci Rep. 2021 Dec 6;11(1):23500. doi: 10.1038/s41598-021-02812-z.

Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.

PLoS Med. 2019 Apr 5;16(4):e1002777. doi: 10.1371/journal.pmed.1002777. eCollection 2019 Apr.

Autosomal dominant polycystic kidney disease.

Lancet. 2019 Mar 2;393(10174):919-935. doi: 10.1016/S0140-6736(18)32782-X. Epub 2019 Feb 25.

Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial.

Int J Cardiol. 2019 Jan 15;275:145-151. doi: 10.1016/j.ijcard.2018.10.063. Epub 2018 Oct 22.

Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.

Lancet. 2013 Nov 2;382(9903):1485-95. doi: 10.1016/S0140-6736(13)61407-5. Epub 2013 Aug 21.

Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease.

Clin J Am Soc Nephrol. 2011 Oct;6(10):2439-43. doi: 10.2215/CJN.01010211. Epub 2011 Sep 8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Octreotide-LAR in ADPKD patients with very low kidney function: a single-center real-life experience.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献